The potential use of biological and chemical weapons is a major concern both on the battlefield and in preparation for domestic terror attacks. Smallpox, anthrax, bubonic and pneumonic plague, and other rarely occuring biological threats loom larger now because they can be made into deadly weapons. A variety of chemical weapons also pose a major threat.
CSC has been providing biodefense solutions to the federal government since 1997 through its subsidiary DynPort Vaccine Company (DVC), a leading biotechnology integrator for the U.S. Government. DVC is working on a variety of vaccines and therapeutics to protect against biological and chemical threat agents and infectious diseases, and offers comprehensive program management solutions.
- Advanced Development - Biological and Chemical Products
- Biodefense Research and Development
- Biotechnology Integration
- Vaccine and Therapeutic Program Management
Representative clients and contracts:
- Department of Health & Human Services (DHHS) - contract to develop seasonal and pandemic influenza vaccines
- DoD Joint Vaccine Acquisition Program (JVAP) - prime systems contract
- DoD Medical Identification and Treatment Systems (MITS) - contract to develop BioScavenger for chemical defense
- National Institute of Allergy & Infectious Diseases (NIAID) - contracts and grants for advanced development of biodefense vaccines
For More Information
Read a case study about the vaccine DVC is developing for pneumonic plague.
Visit the DVC Web site.
Contact us and let our experience help you produce results.